108 related articles for article (PubMed ID: 20819538)
21. Over-expression of RPL23 in myelodysplastic syndromes is associated with apoptosis resistance of CD34+ cells and predicts poor prognosis and distinct response to CHG chemotherapy or decitabine.
Wu L; Li X; Xu F; Chang C; He Q; Zhang Z; Zhang Y
Ann Hematol; 2012 Oct; 91(10):1547-54. PubMed ID: 22580751
[TBL] [Abstract][Full Text] [Related]
22. CD34+ cells from acute myeloid leukemia, myelodysplastic syndromes, and normal bone marrow display different apoptosis and drug resistance-associated phenotypes.
Suárez L; Vidriales MB; García-Laraña J; Sanz G; Moreno MJ; López A; Barrena S; Martínez R; Tormo M; Palomera L; Lavilla E; López-Berges MC; de Santiago M; de Equiza ME; Miguel JF; Orfao A
Clin Cancer Res; 2004 Nov; 10(22):7599-606. PubMed ID: 15569991
[TBL] [Abstract][Full Text] [Related]
23. Expression of Toll-like receptor 9 in bone marrow cells of myelodysplastic syndromes is down-regulated during transformation to overt leukemia.
Kuninaka N; Kurata M; Yamamoto K; Suzuki S; Umeda S; Kirimura S; Arai A; Nakagawa Y; Suzuki K; Kitagawa M
Exp Mol Pathol; 2010 Apr; 88(2):293-8. PubMed ID: 20132814
[TBL] [Abstract][Full Text] [Related]
24. Reduced DNAM-1 expression on bone marrow NK cells associated with impaired killing of CD34+ blasts in myelodysplastic syndrome.
Carlsten M; Baumann BC; Simonsson M; Jädersten M; Forsblom AM; Hammarstedt C; Bryceson YT; Ljunggren HG; Hellström-Lindberg E; Malmberg KJ
Leukemia; 2010 Sep; 24(9):1607-16. PubMed ID: 20613786
[TBL] [Abstract][Full Text] [Related]
25. Impaired clonogenic growth of myelodysplastic bone marrow progenitors in vitro is irrelevant to their apoptotic state.
Michalopoulou S; Micheva I; Kouraklis-Symeonidis A; Kakagianni T; Symeonidis A; Zoumbos NC
Leuk Res; 2004 Aug; 28(8):805-12. PubMed ID: 15203278
[TBL] [Abstract][Full Text] [Related]
26. The clonogenic potential of selected CD34+ cells from patients with MDS appear preserved when tested ex vivo.
Davison GM; Novitzky N; Abdulla R
Leuk Res; 2011 Sep; 35(9):1200-4. PubMed ID: 21474180
[TBL] [Abstract][Full Text] [Related]
27. CD34+CD38-CD123+ Cells Are Present in Virtually All Acute Myeloid Leukaemia Blasts: A Promising Single Unique Phenotype for Minimal Residual Disease Detection.
Al-Mawali A; Pinto AD; Al-Zadjali S
Acta Haematol; 2017; 138(3):175-181. PubMed ID: 29065396
[TBL] [Abstract][Full Text] [Related]
28. Expression of type 1 insulin-like growth factor receptor in marrow nucleated cells in malignant hematological disorders: correlation with apoptosis.
Qi H; Xiao L; Lingyun W; Ying T; Yi-Zhi L; Shao-Xu Y; Quan P
Ann Hematol; 2006 Feb; 85(2):95-101. PubMed ID: 16328478
[TBL] [Abstract][Full Text] [Related]
29. Neutrophil-specific reduction in the expression of granulocyte--macrophage colony-stimulating factor receptor subunits in myelodysplastic syndromes.
Shikama Y; Shichishima T; Ohto H; Jubinsky PT; Maruyama Y
Br J Haematol; 2000 Dec; 111(3):863-72. PubMed ID: 11122148
[TBL] [Abstract][Full Text] [Related]
30. Toll-like receptor-4 is up-regulated in hematopoietic progenitor cells and contributes to increased apoptosis in myelodysplastic syndromes.
Maratheftis CI; Andreakos E; Moutsopoulos HM; Voulgarelis M
Clin Cancer Res; 2007 Feb; 13(4):1154-60. PubMed ID: 17317824
[TBL] [Abstract][Full Text] [Related]
31. Novel variant isoform of G-CSF receptor involved in induction of proliferation of FDCP-2 cells: relevance to the pathogenesis of myelodysplastic syndrome.
Awaya N; Uchida H; Miyakawa Y; Kinjo K; Matsushita H; Nakajima H; Ikeda Y; Kizaki M
J Cell Physiol; 2002 Jun; 191(3):327-35. PubMed ID: 12012328
[TBL] [Abstract][Full Text] [Related]
32. Enhanced expression of mRNA for nuclear factor kappaB1 (p50) in CD34+ cells of the bone marrow in rheumatoid arthritis.
Hirohata S; Miura Y; Tomita T; Yoshikawa H; Ochi T; Chiorazzi N
Arthritis Res Ther; 2006; 8(2):R54. PubMed ID: 16519794
[TBL] [Abstract][Full Text] [Related]
33. Analysis of myeloid and lymphoid markers on the surface and in the cytoplasm of mononuclear bone marrow cells in patients with myelodysplastic syndrome.
Schlesinger M; Silverman LR; Jiang JD; Yagi MJ; Holland JF; Bekesi JG
J Clin Lab Immunol; 1996; 48(4):149-66. PubMed ID: 9819667
[TBL] [Abstract][Full Text] [Related]
34. Transformation of myelodysplastic syndromes into acute myeloid leukemias.
Shi J; Shao ZH; Liu H; Bai J; Cao YR; He GS; Tu MF; Wang XL; Hao YS; Yang TY; Yang CL
Chin Med J (Engl); 2004 Jul; 117(7):963-7. PubMed ID: 15265365
[TBL] [Abstract][Full Text] [Related]
35. Altered responses of purified blast cells from the myelodysplastic syndromes to colony-stimulating factors in vitro: comparison with normal blast cells.
Tohyama K; Ueda T; Yoshida Y; Nakamura T
Exp Hematol; 1994 Jul; 22(7):539-45. PubMed ID: 7516887
[TBL] [Abstract][Full Text] [Related]
36. Antiapoptotic role of growth factors in the myelodysplastic syndromes: concordance between in vitro and in vivo observations.
Tehranchi R; Fadeel B; Schmidt-Mende J; Forsblom AM; Emanuelsson E; Jadersten M; Christensson B; Hast R; Howe RB; Samuelsson J; Zhivotovsky B; Hellström-Lindberg E
Clin Cancer Res; 2005 Sep; 11(17):6291-9. PubMed ID: 16144933
[TBL] [Abstract][Full Text] [Related]
37. CD34+ cell selection is required to assess HOXA9 expression levels in patients with myelodysplastic syndrome.
Heinrichs S; Berman JN; Ortiz TM; Kornblau SM; Neuberg DS; Estey EH; Look AT
Br J Haematol; 2005 Jul; 130(1):83-6. PubMed ID: 15982348
[TBL] [Abstract][Full Text] [Related]
38. Evaluation of the prognostic relevance of L-selectin and ICAM1 expression in myelodysplastic syndromes.
Buccisano F; Maurillo L; Tamburini A; Del Poeta G; Del Principe MI; Ammatuna E; Consalvo MI; Campagna S; Ottaviani L; Sarlo C; Renzi D; Faccia S; Fraboni D; Lo Coco F; Amadori S; Venditti A
Eur J Haematol; 2008 Feb; 80(2):107-14. PubMed ID: 18028430
[TBL] [Abstract][Full Text] [Related]
39. Differential responses of myeloid progenitor cells from patients with myeloid leukemia and myelodysplasia to the costimulating effects of steel factor in vitro.
Maze R; Horie M; Hendrie P; Vadhan-Raj S; Tricot G; Gordon M; Nemunaitis J; Ashman LK; Broxmeyer HE
Exp Hematol; 1993 Apr; 21(4):545-51. PubMed ID: 7681784
[TBL] [Abstract][Full Text] [Related]
40. Enrichment of N-Cadherin and Tie2-bearing CD34+/CD38-/CD123+ leukemic stem cells by chemotherapy-resistance.
Zhi L; Wang M; Rao Q; Yu F; Mi Y; Wang J
Cancer Lett; 2010 Oct; 296(1):65-73. PubMed ID: 20444543
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
